Adamis Pharmaceuticals Corp  

(Public, NASDAQ:ADMP)   Watch this stock  
Find more results for ADMP
4.60
-0.10 (-2.13%)
After Hours: 4.60 0.00 (0.00%)
Aug 16, 4:00PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.43 - 4.65
52 week 2.40 - 6.45
Open 4.65
Vol / Avg. 458,112.00/516,038.00
Mkt cap 144.22M
P/E     -
Div/yield     -
EPS -0.89
Shares 31.35M
Beta 0.06
Inst. own 15%

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -130.64% -300.24%
Operating margin -129.21% -389.32%
EBITD margin - -350.17%
Return on average assets -51.38% -77.99%
Return on average equity -72.92% -120.32%
Employees 14 -
CDP Score - -

Address

11682 El Camino Real Ste 300
SAN DIEGO, CA 92130-2092
United States - Map
+1-858-9972400 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Officers and directors

Richard C. Williams Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Dennis J. Carlo Ph.D. President, Chief Executive Officer, Director
Age: 71
Bio & Compensation  - Reuters
Robert O. Hopkins Chief Financial Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
David J. Marguglio Senior Vice President - Corporate Development, Director
Age: 44
Bio & Compensation  - Reuters
Karen K. Daniels Vice President - Operations
Age: 62
Bio & Compensation  - Reuters
Gus Fernandez Pharm.D. Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Thomas Moll Ph.D. Vice President - Research
Age: 49
Bio & Compensation  - Reuters
William Charles Denby III Independent Director
Age: 60
Bio & Compensation  - Reuters
Robert B. Rothermel Independent Director
Age: 71
Bio & Compensation  - Reuters